Ginkor Fort capsules

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

ginkgo biloba extract, troxerutin, heptaminol hydrochloride

Available from:

Beaufour Ipsen Industrie

ATC code:

C05CA54

INN (International Name):

ginkgo biloba extract, troxerutin, heptaminol hydrochloride

Dosage:

14mg+ 300mg+ 300mg

Pharmaceutical form:

capsules

Units in package:

(30/3x10/), in blister

Prescription type:

OTC

Authorization status:

Registered

Authorization date:

2022-02-02

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF MEDICINAL PREPARATION
GINKOR FORT, capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Standardized Ginkgo biloba extract (EGb 761),
containing 24% ginkgo heterosides and
6% ginkgolides-bilobalides
……………...................................................................
14 мг
Troxerutin
.....................................................................................................................
300 мг
Heptaminol
hydrochloride.............................................................................................
300 мг
For a complete list of excipients, see section 6.1.
3.
DOSAGE FORM
Capsules.
Description: capsule body is opaque yellow, cap is opaque green.
The content of the capsule is a pale yellow powder with a
characteristic odor.
4.
CLINICAL DATA
4.1.
INDICATIONS FOR USE
-
Treatment
of
symptoms
associated
with
venous
lymphatic
insufficiency
(feeling
of
heaviness, paresthesia, leg pain).
- Symptomatic treatment of signs of acute hemorrhoids.
4.2.
DOSAGE REGIMEN AND METHOD OF ADMINISTRATION
- For venous lymphatic insufficiency: 2 capsules per day: one in the
morning, one in the
evening for one to two months, depending on the intensity of the
symptoms.
- Hemorrhoidal crises: distribute the daily dose (3-4 capsules) into
several doses during the
day for 7 days, distributed during meals.
_Application in children _
The drug is not intended for use in children under 18 years of age due
to the lack of data on
efficacy and safety.
4.3.
CONTRAINDICATIONS
-Hypersensitivity to the components of the drug.
-Hyperthyroidism - due to the presence of heptaminol in the
composition. Concomitant use
with monoamine oxidase (MAO) inhibitors (see section 4.5 "Interaction
with other medicinal
products")
.
4.4.
SPECIAL INSTRUCTIONS AND PRECAUTIONS FOR USE
- It is recommended in patients with severe arterial hypertension at
the initial stage of
treatment to carefully monitor the blood pressure level due to the
presence of heptaminol in
the drug.
- Patients w